Grape Seed Extract
Grape Seed Extract (OPCs)
Rich source of oligomeric proanthocyanidins (OPCs) that support circulation, skin health, and antioxidant defense.
Grape Seed Extract is rich in oligomeric proanthocyanidins (OPCs), powerful antioxidants that support blood vessel health, reduce oxidative stress, and support skin collagen. Research shows benefits for circulation, blood pressure, chronic venous insufficiency, and skin aging. One of the most potent antioxidant supplements available.
Mechanisms of Action
OPC Antioxidant Activity
Among the most powerful natural antioxidants
Vascular Support
Strengthens blood vessel walls
Collagen Protection
Protects and supports skin collagen
Recommended Dose
100-300mg (standardized to 95% OPCs)
Optimal Timing
- With meals
Take with food
Best Form
Standardized extract (95% OPCs or proanthocyanidins)
Alternatives: Combined with resveratrol or pine bark
Look for extracts standardized to OPC content. Quality varies between products.
Duration
Minimum: 4 weeks
Optimal: 12 weeks
Cycling: Not required
Note: Can be taken any time of day with food.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Improved Circulation
Better blood flow and reduced leg swelling
Blood Pressure Reduction
Modest decrease in blood pressure
Skin Health
Improved skin elasticity and appearance
Insufficient data; consult doctor
Who Should NOT Take This
- Grape allergy
Drug Interactions
May have mild antiplatelet effects — may affect platelet aggregation or vitamin K-dependent clotting factors, altering anticoagulant efficacy
May have additive blood pressure lowering
Possible Side Effects
Tip: Usually resolves
Tip: Take with food
Tip: May indicate blood pressure reduction
Warnings
- May affect blood clotting — use caution before surgery
- Quality varies — choose standardized extracts
Top studies from 40+ peer-reviewed papers
Martinez-Zapata MJ et al. • The Cochrane database of systematic reviews (2020)
“There is moderate-certainty evidence that phlebotonics probably reduce oedema slightly, compared to placebo; moderate-certainty evidence of little or no difference in QoL; and low-certainty evidence that these drugs do not influence ulcer healing.”
Key Findings:
- Pooled data suggest that phlebotonics probably increase adverse events slightly, compared to placebo (RR 1.14, 95% CI 1.02 to 1.27; 37 studies; 5789 participants; moderate-certainty evidence).
- There is moderate-certainty evidence that phlebotonics probably reduce oedema slightly, compared to placebo; moderate-certainty evidence of little or no difference in QoL; and low-certainty evidence that these drugs do not influence ulcer healing.
- Moderate-certainty evidence suggests that phlebotonics are probably associated with a higher risk of adverse events than placebo.
- Studies included in this systematic review provided only short-term safety data; therefore, the medium- and long-term safety of phlebotonics could not be estimated.
Goudarzi MA et al. • Current drug targets (2024)
“Our study suggests that grape products intake may help to decrease body weight in obese participants.”
Key Findings:
- The outcomes have revealed grape products intake to significantly decrease body weight (p = 0.001) and body mass index (p = 0.004) in obese participants, and also, a greater effect was observed when grape seed extract was used.
- Our study suggests that grape products intake may help to decrease body weight in obese participants.
- Future large RCTs with longer duration and obese populations are needed to expand our findings.
GBD 2019 Lip, Oral, and Pharyngeal Cancer Collaborators et al. • JAMA oncology (2023)
“In this systematic analysis, disparities in LOC and OPC burden existed across the SDI spectrum, and a considerable percentage of burden was attributable to tobacco and alcohol use.”
Key Findings:
- In this systematic analysis, disparities in LOC and OPC burden existed across the SDI spectrum, and a considerable percentage of burden was attributable to tobacco and alcohol use.
- These estimates can contribute to an understanding of the distribution and disparities in LOC and OPC burden globally and support cancer control planning efforts.
- Further research warranted to confirm findings
Angelopoulos N et al. • Nutrients (2023)
“Our results confirm the LDL-C-lowering properties of monacolin are clinically meaningful even in lower doses of 3 mg/day.”
Key Findings:
- LDL-C decreased by 26.46% on average (p < 0.001) during treatment with 10 mg of monacolin and by 16.77% on average during treatment with 3 mg of monacolin (p < 0.001).
- We observed a slight but significant reduction of the triglyceride levels only in the high-dose-treated group (mean -4.25%; 95% CI of mean -11.11 to 2.61).
- No severe adverse events occurred during the study.
- Our results confirm the LDL-C-lowering properties of monacolin are clinically meaningful even in lower doses of 3 mg/day.
Wang TY et al. • NEJM evidence (2023)
“CONCLUSIONS: Apixaban did not demonstrate noninferiority to warfarin and is less effective than warfarin for the prevention of valve thrombosis or thromboembolism in patients with an On-X mechanical aortic valve. (Funded by Artivion; ClinicalTrials.gov number, NCT04142658.)”
Key Findings:
- Most (94%) participants took aspirin.
- A total of 26 primary end-point events occurred, 20 (in 16 participants) in the apixaban group (4.2%/patient-year; 95% confidence interval [CI], 2.3 to 6.0) and 6 (in 6 participants) in the warfarin group (1.3%/patient-year; 95% CI, 0.3 to 2.3).
- The difference in primary end-point rates between the apixaban and warfarin groups was 2.9 (95% CI, 0.8 to 5.0); noninferiority and OPC success criteria were not met.
- Major bleeding rates were 3.6%/patient-year with apixaban and 4.5%/patient-year with warfarin.
Study Type Distribution
Goals This Supplement Supports
Related Goals
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.